1. Introduction {#sec0001}
===============

*Mycobacterium kansasii* is the second most commonly isolated of pathogenic non-tuberculous mycobacteria (NTM), after *Mycobacterium avium complex* (MAC) in patients with the acquired immunodeficiency syndrome (AIDS), and it is the most virulent [@bib0001]. *M. kansasii* usually causes lung disease. Extrapulmonary involvement is rare in immunocompetent adults, but does occur in immunocompetent children and in HIV-infected and other inmmunosuppressed adults [@bib0001], [@bib0002], [@bib0003]. *M. kansasii* is probably the easiest of NTM to treat effectively due to similarities with *M. tuberculosis. M. kansasii* is classically resistant to pyrazinamide (PZA) and sensitive to rifampin (RIF), isoniazid (INH), ethambutol (EMB), macrolides and aminoglycosides \[[@bib0004],[@bib0005]\].

We report here a case of an adult immunocompetent patient with isolated supraclavicular lymphadenitis due to *M. kansasii* resistant to EMB,that was successfully treated with 12 months of RIF+ INH +clarithromycin (CLR) therapy.

2. Case presentation {#sec0002}
====================

A 65-year-old male farmer with mild bronchiectasis was referred to our hospital with a 3 months history of asymptomatic neck mass. The patient was in a perfect state of health except for the cervical lump. He did not have serious infections in the past. A family history of opportunistic infections was not reported. Physical exam revealed a weight of 106 kg and an enlarged right supraclavicular tumor. The mass was soft and not painful to pressure with overlying erythema ([Fig. 1](#fig0001){ref-type="fig"}A). Cervical-thoracic computed tomography (CT) confirmed the presence of right supraclavicular necrotic lymphadenopathy, 36 × 45.7 × 67 mm in diameter ([Fig. 1](#fig0001){ref-type="fig"}B). No other CT cervical or thoracic lymphadenopaties or pulmonary lesions were observed except for mild bibasilar bronchiectasis. A fine needle aspiration (FNA) procedure was performed showing 1--9 acid- fast-bacilli (AFB)/100 high power fields by Ziehl-Neelsen staining of the aspirated pus ([Fig. 1](#fig0001){ref-type="fig"}C).FNA cytology showed granulomatous inflammation. Sputum Ziehl-Neelsen staining, quantitative PCR (qPCR) and culture in Löwenstein-Jensen medium were negative for mycobacteria. A tentative diagnosis of tuberculous lymphadenitis was made and the patient was started on oral INH 300 mg + RIF 600 mg + PZA 1500 mg + EMB 15 mg/kg daily. Routine hemogram and biochemistry values were normal with an ESR of 25 mm/h, and C-reactive protein (C-RP) of 0.7 mg/dl. Quantiferon TB Gold assay and HIV serology were negative.\[Fig. 1\]. A. Right supraclavicular lymphadenopathy, before starting anti-tuberculous therapy; B. Large right necrotic supraclavicular lymph node enlargement (white arrow). The adenopathy compressed the right internal jugular and right brachiocephalic trunk; C. A fine needle aspiration (FNA) procedure was performed showing 1--9 acid- fast-bacilli (AFB)/100 high power fields by Ziehl-Neelsen staining of the aspirated pus; D. Yellow, dry colonies of *M. kansasii* grew in Löwenstein-Jensen medium after 2 weeks after transference from Bactec MGIT 960 medium.Fig 1

Blood levels of IgG, IgM, IgA, complement proteins and granulocytes were normal. Fluorescent-activated cell sorter (FACS) analysis of lymphocytic subpopulations in peripheral blood was normal: CD3^+^ 703/μl (70%), CD4^+^ 367/μl (37%), CD8^+^ 262 μl (26%), ratio CD4^+^/CD8^+^ 1.4. Lymphocytic response to the mitogens phytohemagglutinin, pokeweed, to phorbol myristate acetate + ionomycin and to anti-CD3 monoclonal antibody was normal. Mixed lymphocyte culture stimulated with alloantigens was also normal. A nitroblue tetrazolium test (NBT) done with the patient\'s peripheral WBC was also normal. All these studies ruled out an underlying immunodeficiency.

Two weeks later the FNA pus sample grew *M. kansasii,* confirmed by MALDI-TOF mass spectrophotometry ([Fig. 1](#fig0001){ref-type="fig"}D). A subtype I strain was identified by molecular techniques (INNO-LiPA, Mycobacteria V2, Fujirebio, Gent, Belgium; and GenoType Mycobacterium CM/AS, Hain Lab., Nehren, Germany). Broth microdilution, and/or direct agar proportion method and/or Etest assays showed that the isolate was sensitive to INH, RIF, CLR, streptomycin (STR), doxycycline (DOX), moxifloxacin, (MXF), and linezolid (LZD), and resistant to PZA, EMB, amikacin (AMK), kanamycin (KAN), ciprofloxacin (CIP), levofloxacin (LVX) and tigecycline (TGC). His therapy was switched to INH 300 mg + RIF 600 mg + CLR 500 mg/12 h, which was maintained for 12 months. Oral prednisone 30 mg/d was added during the first 3 months of therapy. A small post-FNA right cervical fistula remained for some months, disappearing along with the neck mass after the first 6 months of therapy. Seven months after the end of treatment he remains well.

3. Discussion {#sec0003}
=============

Ours is the 6th reported case of *M. kansasii* extrapulmonary lymphadenitis in immunocompetent adults; 5 cases in children under 18 have also been reported. ([Table 1](#tbl0001){ref-type="table"}) [@bib0006], [@bib0007], [@bib0008], [@bib0009], [@bib0010], [@bib0011], [@bib0012], [@bib0013], [@bib0014]. Sites of dissemination included cervical and mediastinal lymph nodes, skin, brain, soft tissue, joint, and peritoneum. Two patients had multiple non-nodal sites of involvement; one had concomitant *Salmonella* bacteremia suggesting an acquired defect in T cell immunity, and the work-up for immunodeficiency was not reported for the second case, who relapsed after treatment with INH, RIF and EMB \[[@bib0010],[@bib0012]\].\[Table 1\]Clinical characteristics and outcomes of the reported *Mycobacterium kansasii* lymphadenitis in immunocompetent patients.Table 1Reference/ YearCountryNumber of casesRaceAge (years) /GenderSymptomsLymphadenitis siteOther organs involvedCulture source*M. kansasii* subtypeComorbiditiesEMB sensitivityTherapyDuration (months)OutcomeKanlikama et al.1993 ^6^Turkey2European13.3/NANeck massSubmandibularNoLNNANoNAINH+RIF+ EMBNACureFlint et al.2000 ^7^New Zealand1European2.2/NANeck massNANANANANANAEMB+CLR+surgeryNANAKotb et al.2001 ^8^France1European79/FFever, cough, itching, night sweatsMediastinalSkinLNNANoNAINH+RIF+EMBNANAde Juan et al.2002 ^9^Spain1European2/MNeck mass +spontaneous fistulaLeft lateral cervicalNoLNNANoSensitiveCLR +EMB6CureTabatabael et al.2007 ^10^USA1European74/MFever, somnolence, mental status changesLeft supraclavicular, paratracheal, pretracheal, hilarBrainLNNADiabetes, alcohol abuseSensitiveINH+RIF+EMB18CureSalles et al.2007 ^11^France1European56/FNeck massRight parotid, submaxillaryNoLNIVNoSensitiveRIF+EMB+CLRNANAHsiao et al.2014 ^12^Taiwan1Chinese67/MNeck massCervical, abdomenSoft tissue, lung, joint, peritoneumLNNAHypothyroidism/Salmonella 09 (group D) infectionSensitiveINH+RIF+EMB18Cure/Relapse/Permanent cureBlanc et al.2016 ^13^France1NAAdult, NA age and genderNeck massCervicalNoNANANANANA11Probable cureLoizos et al. 2018 ^14^Cyprus1European17/MNeck massCervicalNoLNNANoNARIF+CLR+ surgery2CureAsensi et al.Spain1European65/MNeck mass + post-FNA fistulaRight supraclavicularNoLNIBronchiectasisResistantINH+RIF+CLR12Cure[^1]

Our patient had subtype I *M. kansasii* lymphadenitis, the subtype most frequently found in humans and the most pathogenic, but rarely isolated from the environment \[[@bib0011],[@bib0015]\].

This is intriguing because he was a farmer and might be exposed to other serotypes of *M. kansasii* by outdoors exposure to contaminated soil and water via aerosol or cutaneous contact or by drinking contaminated lake, river, or even tap water [@bib0001], [@bib0002], [@bib0003]. However, since the node was superclavicular, it is more likely to have spread from a lung focus not seen in the cervico- thoracic CT. Drinking contaminated spring water while farming or eating raw vegetables in contact with contaminated water or soil are other possibilities of having acquired *M. kansasii* infection by this patient.

Quantiferon--TB Gold test was negative in our immunocompetent patient. This is interesting because *M. kansasii* is one of the antigens making the Quantiferon--TB Gold test, a peptide cocktail stimulating the proteins ESAT-6, CFP-10 and TB7.7. The Quantiferon--TB Gold might be positive in *M. kansasii* infections [@bib0016]. However only 52% of the patients with *M.kansasii* disease were positive for the test in one Japanese study [@bib0017].

The *M. kansasii* strain from our case showed EMB resistance by microdilution, direct agar proportion and Etest drug susceptibility methods. CIP, LVX AMK, KAN, and TGC resistances were also observed. Very recently Bakulat et al. reported that *M. kansasii* EMB resistance assessed by broth microdilution and Etest was observed in 83/85 (97.7%) of different subtypes (I to VI, I/II and IIB) of *M. kansasii* strains from **7** European countries and South Korea [@bib0018]. It will be of interest to determine if this high *"in vitro"*resistance of *M. kansasii* to EMB is confirmed in follow-up studies. Resistances to CIP (17/85, 20%) and CLR (1/85, 1.2%) were also reported in the same study.

A case of EMB and INH-resistant *M. kansasii* chronic tenosynovitis in an immunocompetent was reported in 2018 from the USA. The patient, with previous chemical hand skin damage had continuous exposure to a freshwater lake. He was cured with 6 months of CLR ± RIF therapy [@bib0019].

All the seven *M. kansasii* lymphadenitis cases in immunocompetent hosts reported in which the outcome was available were cured. Four of them received 6--18 months of EMB along with RIF and INH and/or CLR and two also underwent surgery with success.

It is no clear presently that there is a gold standard therapy for *M. kansasii* infection. The use of a rifamycin ± a macrolide seems reasonable with the potential addition of EMB [@bib0004]. However, the frequency of EMB resistance needs to be confirmed in additional studies. Some additional caution is also needed because although the European resistance rate to CLR is very low, a 26.8% resistance of *M. kansasii* subtype I to CLR has been recently reported from strains isolated in China [@bib0020].
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[^1]: INH = isoniazid; RIF = rifampin; EMB = ethambutol; CLR = clarythromycin; FNA = fine needle aspiration; NA = not available; M = male, F = female; LN = lymph node.
